Today’s update from Vectura is solid, highlighting respiratory royalty revenue ahead of previous expectations. The merger integration is well underway and expected to generate the targeted £10m of synergies by 2018e. We continue to forecast strong growth, propelled by mainly USD &EUR denominated royalty income from multiple products and flutiform® supply revenue. Key expected newsflow includes the US launch of LABA/LAMA drug Utibron® in H2 2016e and an FDA approval decision for VR315 (2nd to mar ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Vectura Group - Solid AGM update
- Published:
07 Sep 2016 -
Author:
Dr Jens Lindqvist -
Pages:
3
Today’s update from Vectura is solid, highlighting respiratory royalty revenue ahead of previous expectations. The merger integration is well underway and expected to generate the targeted £10m of synergies by 2018e. We continue to forecast strong growth, propelled by mainly USD &EUR denominated royalty income from multiple products and flutiform® supply revenue. Key expected newsflow includes the US launch of LABA/LAMA drug Utibron® in H2 2016e and an FDA approval decision for VR315 (2nd to mar ....